Nicaragua is a second-country option, not a first-in-human starting point. CONIS authorizes medicine trials under NTON 19001:2022 and Normativa-166 after ethics, scientific, and national-regulatory approvals. Section 13.1 requires a foreign product to hold authorization for research in humans from a recognized international regulator before a Nicaragua application, so plan it after an FDA IND or a first study elsewhere. Phase I is provided for, with healthy volunteers first and compassionate use by exception. There are no published device-specific trial rules, though ANRS lists a device clinical-investigation fee code (DDM-10). U.S. sanctions are list-based, so screening is required, and the State Department rates Nicaragua Level 3: Reconsider Travel. This site cites no bioaccess® entity, office, or completed study in Nicaragua.
| Metric | bioaccess® | Nicaragua |
|---|---|---|
| Role in your plan | One First-in-Human CRO that plans the first-in-human country and assesses Nicaragua as a second country for the protocol | One national pathway: CONIS authorization under NTON 19001:2022 and Normativa-166, after ethics, scientific, and ANRS approvals |
| Prior authorization | First-in-human country planned with U.S. regulatory anchoring | A foreign product needs authorization for research in humans from a recognized international regulator before a Nicaragua application (NTON 19001:2022, section 13.1). Whether an FDA IND satisfies that condition is not confirmed in writing |
| Phase I requirements | Confirmed per protocol in the regulatory plan | Healthy volunteers first, compassionate use only by exception; a prior animal toxicity study including carcinogenicity and teratogenicity; an investigator's brochure; and a facility with infrastructure and staff adequate for Phase I (NTON 19001:2022, section 5.2.1; Normativa-166, Chapter VII) |
| Device investigations | Route confirmed case by case with ANRS and CONIS | No published device-specific trial rules. ANRS lists the authorization for the clinical investigation of medical devices at C$10,887.72, code DDM-10 (Circular ANRS-MLRG-0017-10-2024). Import for clinical research needs the CONIS authorization (Resolution 0009/2024) |
| Authority clock | Study-specific; confirmed per protocol | No total timeline published. The ANRS binding technical report is due within 45 business days when CONIS requests it (Normativa-166, Chapter XI). Not an ethics clock or a startup promise |
| Sanctions and travel | Counterparty screening and travel planning built into the feasibility assessment | OFAC's program is list-based, not an embargo: only listed parties and entities they own 50 percent or more are blocked, so screening is required (31 CFR 582.201, 582.406). State Department advisory: Level 3, Reconsider Travel (13 May 2026) |
| Per-patient / program cost | Budget depends on study design; we provide a study-specific quote. | There is no published Nicaragua cost or savings figure on this site; budget follows the protocol |
| Track record in the country | Verified programs are listed in the trial evidence registry | This site cites no bioaccess® entity, office, site, or completed study in Nicaragua |
Comparison uses widely-known category facts about Nicaragua and published US benchmark ranges — not Nicaragua-specific figures. bioaccess® figures reflect our FIH-12™ operating model.
Nicaragua is worth weighing after the first authorization, not before it. NTON 19001:2022 section 13.1 lets a foreign product apply only when it holds authorization for research in humans from a recognized international regulator. That makes Nicaragua a second country after an FDA IND or a first study elsewhere.
The medicine pathway is published. CONIS authorizes the trial after ethics, scientific, and national-regulatory approvals, and Phase I is provided for, with healthy volunteers first, compassionate use by exception, prior animal toxicity including carcinogenicity and teratogenicity, and a facility equipped for Phase I. Device investigations have an ANRS fee code (DDM-10) but no published device-specific rules, so the route is confirmed case by case.
bioaccess® is the same First-in-Human CRO on that file as on the others: Miami headquarters, U.S. regulatory anchoring, and a protocol-specific plan. We make capability and approach statements about Nicaragua, not claims of completed work, a local entity, or an office. Screening under OFAC's list-based program and planning around the State Department's Level 3 advisory are part of that plan.
No. Our Nicaragua page, /clinical-trials-nicaragua, covers the CONIS pathway, the Phase I requirements, the dossier, insurance, and import in detail. This comparison weighs Nicaragua as a destination beside a bioaccess® plan.
Not for a foreign product. NTON 19001:2022 section 13.1 requires authorization for research in humans from a recognized international regulator before a Nicaragua application can be filed. Plan Nicaragua after an FDA IND or a first study elsewhere.
Under NTON 19001:2022 section 5.2.1 and Normativa-166 Chapter VII: a reasoned ethics-committee report, informed consent, a protocol that defines a healthy individual or, by exception, specifies a compassionate-use situation, a detailed protocol, a prior animal toxicity study including carcinogenicity and teratogenicity, the investigator's brochure, and a facility adequate for Phase I.
There are no published device-specific trial rules. ANRS lists the authorization for the clinical investigation of medical devices at C$10,887.72, code DDM-10 (Circular ANRS-MLRG-0017-10-2024), and Resolution 0009/2024 requires the CONIS authorization to import products for clinical research. The route is confirmed case by case with ANRS and CONIS.
This site does not say that. It cites no bioaccess® entity, office, site, or completed study in Nicaragua. Ask for a protocol-specific feasibility assessment.
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call